SRSF10
Serine and Arginine Rich Splicing Factor 10
Gene Information Card
| Symbol | SRSF10 |
|---|---|
| Full Name | Serine and Arginine Rich Splicing Factor 10 |
| Gene Type | protein-coding |
| Chromosomal Location | 1p36.11 |
| NCBI Gene ID | 10772 ncbi.nlm.nih.gov/gene/10772 |
| Ensembl ID | ENSG00000143178 |
| UniProt ID | O75494 |
| OMIM ID | 605221 |
| HGNC ID | 10786 |
| Aliases | SRp38, TASR, SFRS13A, FUSIP1, SRrp40 |
Description
SRSF10 (Serine and Arginine Rich Splicing Factor 10) is a protein-coding gene that encodes a member of the serine/arginine (SR)-rich family of pre-mRNA splicing factors. The protein functions as a sequence-specific RNA-binding protein that regulates both constitutive and alternative splicing. It can act as a splicing activator or repressor depending on phosphorylation status and cellular context. SRSF10 is involved in multiple cellular processes including apoptosis, cell cycle control, and stress response. Dysregulation of SRSF10 has been implicated in various cancers and neurodegenerative disorders.
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| Breast cancer | Altered splicing of oncogenes and tumor suppressors via SRSF10 overexpression | PMID: 25609608 |
| Colorectal cancer | SRSF10 promotes cell proliferation and invasion through alternative splicing of CD44 | PMID: 28925356 |
| Hepatocellular carcinoma | SRSF10 upregulation correlates with poor prognosis and modulates splicing of apoptotic factors | PMID: 30120210 |
| Glioblastoma | SRSF10 regulates splicing of MDM4, affecting p53 pathway | PMID: 31073040 |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Testis | 15.2 | Medium |
| Brain | 10.8 | Medium |
| Lung | 8.5 | Medium |
| Liver | 6.3 | Low |
| Heart | 5.1 | Low |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| HEK293 | 12.4 | Embryonic kidney cells |
| HeLa | 9.7 | Cervical cancer cells |
| MCF7 | 11.2 | Breast cancer cells |
| HepG2 | 7.8 | Hepatocellular carcinoma cells |
Data source：Human Protein Atlas（proteinatlas.org）
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| c.487C>T (p.Arg163Trp) | Missense | <0.01% | Potential loss of RNA-binding affinity (ClinVar) |
| c.632A>G (p.Lys211Arg) | Missense | <0.01% | Unknown significance (ClinVar) |
| c.1A>G (p.Met1Val) | Start loss | <0.01% | Likely loss of function (ClinVar) |
Mutation functional classification
Loss of Function (LOF)
Missense mutations in the RRM domain (e.g., p.Arg163Trp) may impair RNA binding and splicing regulation.
Gain of Function (GOF)
Not well characterized; overexpression in cancers suggests potential gain-of-function via increased splicing activity.
Dominant Negative (DN)
No confirmed dominant-negative mutations reported.
View complete mutation data：
Gene Ontology (GO)
| • RNA binding | • mRNA splicing |
| • via spliceosome | • alternative mRNA splicing |
| • nucleus | • nuclear speck |
| • protein binding |
Pathways
• mRNA Splicing - Major Pathway
• Alternative Splicing
• Apoptosis
Protein Summary
SRSF10 encodes a 262-amino acid protein (SRp38) with an N-terminal RNA recognition motif (RRM) and a C-terminal arginine/serine-rich (RS) domain. The protein shuttles between the nucleus and cytoplasm and is phosphorylated by SRPK1 and CLK kinases. Dephosphorylation of SRSF10 converts it from a splicing activator to a repressor. It regulates alternative splicing of genes involved in apoptosis (e.g., BCL2L1, CASP9) and cell cycle (e.g., CD44, MDM4).
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| SRSF10 Knockout HEK293 Cell Line | EDJ-KQ3279 | Human | 10772 | Details Get a Quote |
| SRSF10 Knockout HCT 116 Cell Line | EDJ-KQ24834 | Human | 10772 | Details Get a Quote |
| SRSF10 Knockout HeLa Cell Line | EDJ-KQ24835 | Human | 10772 | Details Get a Quote |
| SRSF10 Knockout A-549 Cell Line | EDJ-KQ63971 | Human | 10772 | Details Get a Quote |
Displaying Records 1 To 4 Of 4 Records
